健择联合顺铂治疗晚期非小细胞肺癌疗效分析

Efficacy of gemcitabine and cisplatine as intensive weekly chemotherapy for advanced non-small cell lung cancer

目的:观察健择(gemcitabine,GEM)/顺铂(DDP)每周给药方案治疗晚期非小细胞肺癌(nonsmallcelllungcancel,NSCLC)的近期疗效和毒性反应。方法:37例晚期NSCLC,分别于d1、d8和d15联合应用GEM(1000mg/m2)和DDP(25mg/m2),28d为1个周期。治疗至少2个周期评价疗效。结果:36例可评价疗效,所有患者无CR,PR12例,NC15例,PD9例,总有效率为33.3%(12/36)。37例可评价毒性,3、4度粒细胞减少、血小板减少分别为13.5%(5/37)和16.2%(6/37)。结论:GEM/DDP每周给药方案疗效与其他GEM/DDP联合方案疗效相仿,但毒性反应明显低于其他方案,可用于老年患者或一般状况较差患者的治疗。

OBJECTIVE:To evaluate the efficacy and toxicities of Gemcitabine plus Cisplatine as intensive weekly regimen for patients with advanced NSCLC.METHODS:37 patients were enrolled into this study. Gemcitabine (1 000 mg/m 2) and Cisplatine (25 mg/m 2) were administered at day 1,8 and 15. Each cycle takes 28 days. Patients were evaluated after at least 2 cycles.RESULTS:36 cases were evaluated. Respons rate to this weekly intensively regimen was 33.3%(12/36), with 0 CR and 12 PR. The incidence of grade 3 and 4 neutropenia and thrombocytopenia was 13.5%(5/37) and 16.2%(6/37) respectively. CONCLUSIONS:The efficacy of GEM/DDP weekly regimen is similar to that of others GEM/DDP combination regimens, but toxicities of this regimen are much lower than those of others. GEM/DDP weekly intensive regimen may be helpful for elder and weaker patients with advanced NSCLC.